- Myasthenia gravis, an autoimmune neuromuscular disorder characterized by muscle weakness and fatigue, is seeing increased demand for effective diagnostics and treatments due to rising global incidence and improved healthcare access
- The market is fueled by advancements in immunosuppressive therapies, biologics, and minimally invasive surgical techniques, alongside growing patient awareness and early diagnosis initiatives
- North America dominated the myasthenia gravis disease market with the largest revenue share of 42.5% in 2024, driven by advanced healthcare infrastructure, high adoption of novel therapies, and the presence of key market players. The U.S. leads in research and development, with significant investments in biologics and clinical trials
- Asia-Pacific is expected to be the fastest-growing region during the forecast period, attributed to increasing healthcare investments, rising awareness, and growing prevalence of autoimmune disorders due to urbanization and lifestyle changes
- The blood test segment dominated the largest market revenue share of 38.5% in 2024, driven by its high sensitivity in detecting acetylcholine receptor antibodies, which are present in approximately 85-90% of patients with generalized myasthenia gravis
